Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
762.63
+24.29 (3.29%)
At close: Jul 31, 2026, 4:00 PM EDT
761.45
-1.18 (-0.16%)
After-hours: Jul 31, 2026, 7:49 PM EDT

Regeneron Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
15,53514,34314,20213,11712,17316,072
Revenue Growth
9.29%0.99%8.27%7.76%-24.26%89.14%
Cost of Revenue
2,3522,1011,9711,8161,5602,438
Gross Profit
13,18312,24212,23211,30110,61313,634
Selling, General & Admin
2,7432,7002,9542,6312,1161,825
Research & Development
6,6075,9745,2334,6253,8482,908
Other Operating Expenses
--1053.4-2.1-89.9-45.6
Total Operating Expenses
9,3508,6648,2417,2545,8744,687
Operating Income
3,8433,5783,9914,0474,7398,947
Interest Expense
-55.4-43.8-55.2-73-59.4-57.3
Other Non-Operating Income (Expense)
1,3781,697844.4225.2179.3436.3
Total Non-Operating Income (Expense)
1,3231,653789.2152.2119.9379
Pretax Income
5,1665,2314,7804,1994,8599,326
Provision for Income Taxes
837.3725.8367.3245.7520.41,251
Net Income
4,3294,5054,4133,9544,3388,075
Net Income to Common
4,3294,5054,4133,9544,3388,075
Net Income Growth
-2.91%2.09%11.61%-8.87%-46.28%129.86%
Shares Outstanding (Basic)
103105108107107106
Shares Outstanding (Diluted)
107109115114114112
Shares Change
-4.76%-5.65%1.23%0.18%1.16%-2.52%
EPS (Basic)
41.9143.0740.9037.0540.5176.40
EPS (Diluted)
40.4641.4838.3434.7738.2271.97
EPS Growth
1.97%8.19%10.27%-9.03%-46.89%135.81%
Free Cash Flow
3,7604,0813,6653,8754,4256,529
Free Cash Flow Growth
-2.42%11.35%-5.44%-12.42%-32.23%225.90%
Free Cash Flow Per Share
35.1137.5731.8434.0838.9858.19
Dividends Per Share
3.6403.520----
Dividend Growth
106.82%-----
Gross Margin
84.86%85.35%86.13%86.16%87.18%84.83%
Operating Margin
24.74%24.95%28.10%30.85%38.93%55.67%
Profit Margin
27.86%31.41%31.07%30.14%35.64%50.25%
FCF Margin
24.21%28.45%25.80%29.54%36.35%40.63%
EBITDA
4,3724,1224,4744,4685,0809,233
EBITDA Margin
28.14%28.74%31.50%34.06%41.73%57.45%
EBIT
3,8433,5783,9914,0474,7398,947
EBIT Margin
24.74%24.95%28.10%30.85%38.93%55.67%
Effective Tax Rate
16.21%13.88%7.68%5.85%10.71%13.41%
SEC Filings: 10-K · 10-Q